1 / 42

PSYCHOSIS

PSYCHOSIS. # A syndrome of chronic disordered thinking and disturbed behavior (schizophrenia, mania, depression) Deficits in integrating thought and perception with emotion (some refer to a loss of “cognitive control”)  paranoid delusions/thought insertion/ideas of reference

laszlo
Télécharger la présentation

PSYCHOSIS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PSYCHOSIS #A syndrome of chronic disordered thinking and disturbed behavior (schizophrenia, mania, depression) • Deficits in integrating thought and perception with emotion (some refer to a loss of “cognitive control”) paranoid delusions/thought insertion/ideas of reference hallucinations (generally auditory, but can be visual) loss of affect/poverty of speech/social withdrawal impaired ability to function with others idiopathic or organic etiology • Prevalence of schizophrenia: 1% of population worldwide

  2. MENTAL ILLNESSES • Environmental factors • Maturational factors • Neuronal connectivity • Neurotransmitters • Receptors/drug targets

  3. Schizophrenia Environmental Factors Exposure to infections Toxic/Traumatic ( in utero)Insults ALTERATIONS IN NEURODEVELOPMENT Autoimmunity Stress during gestation or early in childhood/adolescence

  4. Maturational Processes Apoptosis Synaptic Pruning Myelination (prenatal to adolescence) Unmasking Genetic Vulnerability

  5. Neuronal Plasticity • Structural changes during development and in response to environmental factors • Changes in neurotransmitter activity in response to environmental factors • Neurotrophic factors and changes in gene transcription • (eg. neuroregulin-1 which regulates neuronal migration) • Continues throughout life of the organism • Underlies learning and memory

  6. NEURONAL CONNECTIVITY • Functional activity in neocortex of schizophrenic patients may be decreased • Myelination • Synaptic pruning • Hormonal effects of puberty • Exposure to stressors • Defective connections in midbrain, nucleus accumbens, thalamus, temporo-limbic and prefrontal cortex

  7. STRUCTURAL BRAIN CHANGES IN SCHIZOPHRENIA • Schizophrenics show deficits in tasks involving prefrontal cortex or those requiring working memory • Prefrontal cortical thickness is reduced 5-10%, neuron size is down, but no change in neuron number • Synaptic connectivity is reduced • Medial dorsal thalamus shows 30% reduction in neuron number • Prefrontal cortex receives fewer projections from the thalamus • Hippocampus shows altered cytoarchitecture

  8. The Dopamine Hypothesis • Schizophrenia results from excess activity of dopamine neurotransmission because: • ALL antipsychotic drugs block dopamine receptors. • Stimulant drugs which act through dopamine can produce schizophrenic-like behaviors (eg.amphetamines). • Levodopa, a dopamine precursor, can exacerbate schizophrenic symptoms, or occasionally elicit them in non-schizophrenic patients. • Higher levels of dopamine receptors measured in brains of schizophrenics. • Brain [DA] increases during psychotic episodes but not during remissions.

  9. A HYPOTHESIS IN TRANSITION • All antipsychotic drugs which block dopamine receptors do not reverse all symptoms • positives are more responsive • negatives may even be exacerbated • Antipsychotics blocking DA and 5-HT receptors seem better for both positive and negative symptoms • NMDA glutamate--based on effects of PCP in humans • DA metabolites in CSF & plasma not significantly elevated in schizophrenics • Antipsychotic drugs block DA receptors immediately but antipsychotic benefits take several days to weeks to occur

  10. New Findings Polymorphism of COMT gene with increased activity and more efficient metabolism of DA leading to: lower than normal prefrontal cortex DA release=hypofrontality Polymorphism of -7 nAChR on chromosome 15 as cause of disturbance in sensory gating=normalized by nicotine Partial D-2 agonist and 5-HT-2/5-HT-1a antagonist effective for positive/negative symptomatology

  11. DOPAMINE RECEPTORS: THE HOLY GRAIL FOR ANTIPSYCHOTIC MEDS? • Dopamine recognized as a neurotransmitter in the 1950’s • Five dopamine receptor subtypes: D-1,-2,-3,-4,-5 • Drug naive schizophrenics show elevated D2 receptor number • Cortex has much higher amounts of D1 than D2 receptors • chronic antipsychotic drugs downregulate D1’s in the cortex and striatum

  12. THE HOLY GRAIL FOR MEDS, CONT’D • Striatum has high concentrations of D1 & D2 receptors • All effective antipsychotics possess some threshold level of D2 receptor blockade • striatal D2s may be the site for antipsychotic drug-induced movement disorders • clozapine upregulates cortical D2s at doses that do not affect striatal D2s • Limbic structures contain high concentrations of D4s • clozapine has high affinity for D4s, but selective D4 antagonists fail to show antipsychotic efficacy • Serotonin inhibits dopamine neurotransmission • atypicals show serotonin binding ability

  13. DRUG TARGETS,CONT’D • The newer “atypicals” have the ability to block the behavioral effects of phencyclidine (PCP) • PCP elicits behavioral/ cognitive symptoms indistinguishable from schizophrenia • PCP is an uncompetitive blocker of NMDA-glutamate ion channel function

  14. NEUROTRANSMITTERS • Overactivity of dopamine in limbic regions (positive symptoms?) • Abnormalities in dopamine storage, vesicular transport, release or reuptake • NMDA-glutamate hypofunction (negative symptoms?)

  15. ANTIPSYCHOTIC DRUGS • no compound can target a given symptom • therapeutic effects correlated to potency at D-2 dopamine receptors • all have effects on other non-dopamine receptors (side-effects, or therapeutic effects) • can also be used for Tourette’s, control of acute mania, intractable hiccups, choreas and ballisms

  16. DRUG TARGETS • Dopamine receptors: D1, D2, D3, D4, D5 • Serotonin receptors: 5-HT-1A, 2A, 3, 6, 7 • Norepinephrine: -1 & -2 • Muscarinic acetylcholine: mACh-1 & 4 • Histamine: H-1 & 2 • Dopamine, norepinephrine & serotonin transporters • NMDA-glutamate receptor

  17. DopamineReceptors Occupancy—therapeutic vs. side effects At therapeutic doses the “classical” antipsychotics occupy >75% of dopamine D-2 receptors. 85% occupancy needed to get extrapyramidal side effects. Clozapine, the “atypical”, blocks only 35% D-2 receptors at therapeutic doses.

  18. DRUG CLASSES • Phenothiazines: eg. chlorpromazine • Thioxanthenes • Butyrophenones: eg. haloperidol • Diphenylbutylpiperidine • Dihydroindolone • Dibenzoxazepines: eg. clozapine • Benzisoxazol: eg. risperidone

  19. PHARMACOLOGICAL PROPERTIES • Neuroleptic syndrome: • suppression of spontaneous behavior • loss of initiative and interest (anhedonia) • loss of affect and emotional content • slowness of movement • Parkinson-like extrapyramidal effects • Unpleasant when given to non-psychotic individual

  20. TYPE MANIFESTATIONS MECHANISM

  21. Low Potency Fewer extrapyramidal reactions (especially thioridazine) More sedation, more postural hypotension Greater effect on the seizure threshold, electrocardiogram (especially thioridazine) More likely skin pigmentation and photosensitivity Occasional cases of cholestatic jaundice Rare cases of agranulocytosis High Potency More frequent extrapyramidal reactions Less sedation, less postural hypotension Less effect on the seizure threshold, less cardiovascular toxicity Fewer anticholinergic effects Occasional cases of neuroleptic malignant syndrome Spectrum of Adverse Effects Caused by Antipsychotic Drugs

  22. SIDE EFFECTS, cont’d. • Parkinsonian syndrome • neuroleptic malignant syndrome • akathisia • acute dystonic reactions • tardivie dyskinesia

  23. Tardive dystonia Strikes younger Strikes sooner in the course of neuroleptic treatment Poor prognosis More males Patients with mood disorders may be more susceptible Anticholinergics may improve condition Tardive dyskinesia Strikes older Strikes later in the course of neuroleptic treatment Variable prognosis More females (?) Patients with mood disorders may be more susceptible Anticholinergics usually worsen condition Comparison of Tardive Dystonia and Tardive Dyskinesia

  24. Tardive dystonia Strikes younger Strikes sooner in the course of neuroleptic treatment Poor prognosis More males Patients with mood disorders may be more susceptible Anticholinergics may improve condition Tardive dyskinesia Strikes older Strikes later in the course of neuroleptic treatment Variable prognosis More females (?) Patients with mood disorders may be more susceptible Anticholinergics usually worsen condition TABLE 6. Comparison of Tardive Dystonia and Tardive Dyskinesia

  25. SIDE EFFECTS • Autonomics--related to blockade of alpha- adrenergic and muscarinic receptors • Endocrine effects, primarily prolactin increases • Disruption of thermoregulatory control • Hypersensitivity reactions; eg. agranulocytosis with clozapine; browning of vision with thioridizine

  26. Stress & Schizophrenia Schizophrenic patients have altered sensitivity to stress • They display abnormalities in autonomic nervous system and hypothalmic-pituitary adrenal function in response to stress • Coping abilities seem best preserved in schizophrenics who suffer the least negative symptoms • Cognitive deficits in schizophrenics may cause them to be less well adapted to their environment • Schizophrenics have difficulty filtering incoming sensory stimuli

  27. Indications for Antipsychotic Drugs Schizophrenia Schizoaffective disorders Acute control of mania Tourette’s syndrome Huntington’s chorea and ballism Intractable hiccups

More Related